Olanzapină (Romanian Wikipedia)
Analysis of information sources in references of the Wikipedia article "Olanzapină" in Romanian language version.
refsWebsite
Global rank
Romanian rank
1st place
1st place
3,258th place
1,726th place
7,927th place
5,692nd place
719th place
901st place
8,573rd place
247th place
6,663rd place
low place
3,984th place
low place
3rd place
6th place
low place
low place
3,912th place
6,145th place
low place
low place
low place
low place
low place
low place
3,823rd place
9,399th place
low place
low place
3,538th place
3,279th place
7th place
25th place
aspetjournals.org
dmd.aspetjournals.org
- Kassahun K, Mattiuz E, Nyhart E (). DISPOSITION AND BIOTRANSFORMATION OF THE ANTIPSYCHOTIC AGENT OLANZAPINE IN HUMANS. Drug Metabolism and Disposition. p. 81.
astrazenecaclinicaltrials.com
- AstraZeneca Pharmaceuticals (4 aprilie 2006). „Efficacy and Tolerability of Olanzapine, Quetiapine and Risperidone in the Treatment of First Episode Psychosis: A Randomised Double Blind 52 Week Comparison”. AstraZeneca Clinical Trials. AstraZeneca PLC. Arhivat din original la 13-11-2007. Accesat în 3 decembrie 2007.
At week 12, the olanzapine-treated group had more weight gain, a higher increase in [ body mass index ], and a higher proportion of patients with a BMI increase of at least 1 unit compared with the quetiapine and risperidone groups (p<=0.01).
Verificați datele pentru:|archive-date=(ajutor)
bbc.co.uk
news.bbc.co.uk
- „Doctors 'ignoring drugs warning'”. BBC News. 17 iunie 2008. Accesat în 22 iunie 2008. Verificați datele pentru:
|access-date=(ajutor)
books.google.com
- Taylor D, Paton C, Kapur S (). The Maudsley Prescribing Guidelines in Psychiatry (ed. 12th). London, U K: Wiley-Blackwell. p. 16. ISBN 978-1-118-75460-3.
chemspider.com
- Olanzapine (în engleză), ChemSpider, accesat în
clincalc.com
- „The Top 300 of 2019”. clincalc.com. Accesat în .
doi.org
- Callaghan JT, Bergstrom RF, Ptak LR, et al. (Septembrie 1999). „Olanzapine: pharmacokinetic and pharmacodynamic profile”. Clin Pharmacokinetics. 37 (3): 177–193. doi:10.2165/00003088-199937030-00001. PMID 10511917. Verificați datele pentru:
|date=(ajutor) - Mauri MC, Volonteri LS, Colasanti A, et al. (). „Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response”. Clinical Pharmacokinetics. 46 (5): 359–88. doi:10.2165/00003088-200746050-00001. PMID 17465637.
- Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. (Septembrie 2013). „Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis”. Lancet. 382 (9896): 951–62. doi:10.1016/S0140-6736(13)60733-3. PMID 23810019. Verificați datele pentru:
|date=(ajutor) - Harvey RC, James AC, Shields GE (Ianuarie 2016). „A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia”. CNS Drugs. 30 (1): 27–39. doi:10.1007/s40263-015-0308-1. PMID 26801655. Verificați datele pentru:
|date=(ajutor) - Pagsberg AK, Tarp S, Glintborg D, Stenstrøm AD, Fink-Jensen A, Correll CU, Christensen R (martie 2017). „Acute Antipsychotic Treatment of Children and Adolescents With Schizophrenia-Spectrum Disorders: A Systematic Review and Network Meta-Analysis”. Journal of the American Academy of Child and Adolescent Psychiatry. 56 (3): 191–202. doi:10.1016/j.jaac.2016.12.013. PMID 28219485.
- Osser DN, Roudsari MJ, Manschreck T (). „The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia”. Harvard Review of Psychiatry. 21 (1): 18–40. doi:10.1097/HRP.0b013e31827fd915. PMID 23656760.
- Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S (Aprilie 2005). „Olanzapine for schizophrenia”. The Cochrane Database of Systematic Reviews (2): CD001359. doi:10.1002/14651858.CD001359.pub2. PMID 15846619. Verificați datele pentru:
|date=(ajutor) - Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S (Martie 2010). „Olanzapine versus other atypical antipsychotics for schizophrenia”. The Cochrane Database of Systematic Reviews (3): CD006654. doi:10.1002/14651858.CD006654.pub2. PMC 4169107
. PMID 20238348. Verificați datele pentru: |date=(ajutor) - Barnes TR (). „Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology” (PDF). J. Psychopharmacol. (Oxford). 25 (5): 567–620. doi:10.1177/0269881110391123. PMID 21292923.[nefuncțională]
- Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Möller HJ (). „World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects”. World J. Biol. Psychiatry. 14 (1): 2–44. doi:10.3109/15622975.2012.739708. PMID 23216388.
- Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU (iulie 2013). „Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis”. Int. J. Neuropsychopharmacol. 16 (6): 1205–18. doi:10.1017/S1461145712001277. PMC 3594563 . PMID 23199972.
- Citrome L (august 2012). „A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia”. Expert Opin Pharmacother. 13 (11): 1545–73. doi:10.1517/14656566.2011.626769. PMID 21999805.
- Lepping P, Sambhi RS, Whittington R, Lane S, Poole R (mai 2011). „Clinical relevance of findings in trials of antipsychotics: systematic review”. Br J Psychiatry. 198 (5): 341–5. doi:10.1192/bjp.bp.109.075366. PMID 21525517.
- Désaméricq G, Schurhoff F, Meary A, Szöke A, Macquin-Mavier I, Bachoud-Lévi AC, Maison P (Februarie 2014). „Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis”. European Journal of Clinical Pharmacology. 70 (2): 127–34. doi:10.1007/s00228-013-1600-y. PMID 24145817. Verificați datele pentru:
|date=(ajutor) - Yatham LN, Kennedy SH, O'Donovan C, et al. (Decembrie 2006). „Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007”. Bipolar Disord. 8 (6): 721–39. doi:10.1111/j.1399-5618.2006.00432.x. PMID 17156158. Verificați datele pentru:
|date=(ajutor) - Selle V, Schalkwijk S, Vázquez GH, Baldessarini RJ (Martie 2014). „Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics”. Pharmacopsychiatry. 47 (2): 43–52. doi:10.1055/s-0033-1363258. PMID 24549862. Verificați datele pentru:
|date=(ajutor) - Morin, Anna K (Martie 2014). „Off-label use of atypical antipsychotic agents for treatment of insomnia”. Mental Health Clinician. 4 (2): 65–72. doi:10.9740/mhc.n190091. Verificați datele pentru:
|date=(ajutor) - Rasmussen SA, Chu SY, Kim SY, Schmid CH, Lau J (Iunie 2008). „Maternal obesity and risk of neural tube defects: a metaanalysis”. American Journal of Obstetrics & Gynecology. 198 (6): 611–619. doi:10.1016/j.ajog.2008.04.021. PMID 18538144. Verificați datele pentru:
|date=(ajutor) - McMahon DM, Liu J, Zhang H, Torres ME, Best RG (Februarie 2013). „Maternal obesity, folate intake, and neural tube defects in offspring”. Birth Defects Research Part A: Clinical and Molecular Teratology. 97 (2): 115–122. doi:10.1002/bdra.23113. PMID 23404872. Verificați datele pentru:
|date=(ajutor) - Yeung EY, Chun S, Douglass A, Lau TE (08-05-2017). „Effect of atypical antipsychotics on body weight in geriatric psychiatric inpatients”. SAGE Open Medicine. 5: 2050312117708711. doi:10.1177/2050312117708711. PMC 5431608 . PMID 28540050. Verificați datele pentru:
|date=(ajutor) - Stöllberger C, Lutz W, Finsterer J (Iulie 2009). „Heat-related side-effects of neurological and non-neurological medication may increase heatwave fatalities”. European Journal of Neurology. 16 (7): 879–82. doi:10.1111/j.1468-1331.2009.02581.x. PMID 19453697. Verificați datele pentru:
|date=(ajutor) - Ramankutty G (). „Olanzapine-induced destabilization of diabetes in the absence of weight gain”. Acta Psychiatrica Scandinavica. 105 (3): 235–6; discussion 236–7. doi:10.1034/j.1600-0447.2002.2c257a.x. PMID 11939979.
- Lambert MT, Copeland LA, Sampson N, Duffy SA (). „New-onset type-2 diabetes associated with atypical antipsychotic medications”. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 30 (5): 919–23. doi:10.1016/j.pnpbp.2006.02.007. PMID 16581171.
- Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, Mintz J, Marder SR (). „Novel Antipsychotics”. The Journal of Clinical Psychiatry. 60 (6): 358–63. doi:10.4088/JCP.v60n0602. PMID 10401912.
- McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowski SD (Iulie 2007). „Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison”. The American Journal of Psychiatry. 164 (7): 1050–60. doi:10.1176/ajp.2007.164.7.1050. PMID 17606657. Verificați datele pentru:
|date=(ajutor) - Fulbright AR, Breedlove KT (). „Complete Resolution of Olanzapine-Induced Diabetic Ketoacidosis”. Journal of Pharmacy Practice. 19 (4): 255–8. doi:10.1177/0897190006294180.
- Chiu CC, Chen CH, Chen BY, Yu SH, Lu ML (august 2010). „The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine”. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 34 (6): 866–70. doi:10.1016/j.pnpbp.2010.04.003. PMID 20394794.
- Sacher J, Mossaheb N, Spindelegger C, Klein N, Geiss-Granadia T, Sauermann R, Lackner E, Joukhadar C, Müller M, Kasper S (iunie 2008). „Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers”. Neuropsychopharmacology. 33 (7): 1633–41. doi:10.1038/sj.npp.1301541. PMID 17712347.
- Sowell M, Mukhopadhyay N, Cavazzoni P, Carlson C, Mudaliar S, Chinnapongse S, Ray A, Davis T, Breier A, Henry RR, Dananberg J (Decembrie 2003). „Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp”. The Journal of Clinical Endocrinology and Metabolism. 88 (12): 5875–80. doi:10.1210/jc.2002-021884. PMID 14671184. Verificați datele pentru:
|date=(ajutor) - de Haan L, van Amelsvoort T, Rosien K, Linszen D (). „Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets”. Psychopharmacology. 175 (3): 389–90. doi:10.1007/s00213-004-1951-2. PMID 15322727.
- Luedecke, D; Schöttle, D; Karow, A; Lambert, M; Naber, D (ianuarie 2015). „Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management”. CNS Drugs. 29 (1): 41–6. doi:10.1007/s40263-014-0216-9. PMID 25424243.
- Brambilla G, Mattioli F, Martelli A (). „Genotoxic and carcinogenic effects of antipsychotics and antidepressants”. Toxicology. 261 (3): 77–88. doi:10.1016/j.tox.2009.04.056. PMID 19410629.
- Moncrieff J (Iulie 2006). „Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse”. Acta Psychiatrica Scandinavica. 114 (1): 3–13. doi:10.1111/j.1600-0447.2006.00787.x. PMID 16774655. Verificați datele pentru:
|date=(ajutor)
drugs.com
- Drugs.com Drugs.com international listings for Olanzapine Pagină accesată pe 4 august 2015
- „Olanzapine, Olanzapine Pamoate Monograph for Professionals”. Drugs.com (în engleză). AHFS. Accesat în .
- „Olanzapine Monograph for Professionals - Drugs.com”. Drugs.com. Accesat în .
- Cerner Multum Incorporated (). „Olanzapine”. Drugs.com.
ebi.ac.uk
- olanzapine (în engleză), ChEBI, accesat în
- OLANZAPINE (în engleză), ChEMBL, accesat în
eurekalert.org
- „NIMH study to guide treatment choices for schizophrenia” (Press release). National Institute of Mental Health. 19 septembrie 2005. Accesat în 18 decembrie 2006. Verificați datele pentru:
|access-date=(ajutor)
fda.gov
- olanzapine (în engleză), Global Substance Registration System, accesat în
google.ca
books.google.ca
- Haddad, Peter; Haddad, Peter M.; Dursun, Serdar; Deakin, Bill (). Adverse Syndromes and Psychiatric Drugs: A Clinical Guide (în engleză). OUP Oxford. p. 207-216. ISBN 9780198527480.
- Sacchetti, Emilio; Vita, Antonio; Siracusano, Alberto; Fleischhacker, Wolfgang (). Adherence to Antipsychotics in Schizophrenia (în engleză). Springer Science & Business Media. p. 85. ISBN 9788847026797.
medicaid.gov
data.medicaid.gov
- „NADAC as of 2018-12-19”. Centers for Medicare and Medicaid Services (în engleză). Arhivat din original la . Accesat în .
medicines.org.uk
- „Olanzapine 10 mg tablets - Summary of Product Characteristics (SPC)”. electronic Medicines Compendium. Aurobindo Pharma - Milpharm Ltd. . Accesat în .
medscape.com
reference.medscape.com
- „Zyprexa, Zyprexa Relprevv (olanzapine) dosing, indications, interactions, adverse effects, and more”. Medscape Reference. WebMD. Accesat în .
medscape.com
- Moyer, Paula (25 oct 2005). „CAFE Study Shows Varying Benefits Among Atypical Antipsychotics”. Medscape Medical News. WebMD. Accesat în 3 decembrie 2007. Verificați datele pentru:
|access-date=(ajutor)
nice.org.uk
- National Collaborating Centre for Mental Health (). „Schizophrenia: Full national clinical guideline on core interventions in primary and secondary care” (PDF). Accesat în .
- „Psychosis and schizophrenia in adults: treatment and management | Guidance and guidelines | NICE”. National Institute for Health and Care Excellence.
- „Bipolar disorder: the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care | 1-recommendations | Guidance and guidelines | NICE”. Accesat în .
nih.gov
ncbi.nlm.nih.gov
- Callaghan JT, Bergstrom RF, Ptak LR, et al. (Septembrie 1999). „Olanzapine: pharmacokinetic and pharmacodynamic profile”. Clin Pharmacokinetics. 37 (3): 177–193. doi:10.2165/00003088-199937030-00001. PMID 10511917. Verificați datele pentru:
|date=(ajutor) - Mauri MC, Volonteri LS, Colasanti A, et al. (). „Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response”. Clinical Pharmacokinetics. 46 (5): 359–88. doi:10.2165/00003088-200746050-00001. PMID 17465637.
- Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. (Septembrie 2013). „Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis”. Lancet. 382 (9896): 951–62. doi:10.1016/S0140-6736(13)60733-3. PMID 23810019. Verificați datele pentru:
|date=(ajutor) - Harvey RC, James AC, Shields GE (Ianuarie 2016). „A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia”. CNS Drugs. 30 (1): 27–39. doi:10.1007/s40263-015-0308-1. PMID 26801655. Verificați datele pentru:
|date=(ajutor) - Pagsberg AK, Tarp S, Glintborg D, Stenstrøm AD, Fink-Jensen A, Correll CU, Christensen R (martie 2017). „Acute Antipsychotic Treatment of Children and Adolescents With Schizophrenia-Spectrum Disorders: A Systematic Review and Network Meta-Analysis”. Journal of the American Academy of Child and Adolescent Psychiatry. 56 (3): 191–202. doi:10.1016/j.jaac.2016.12.013. PMID 28219485.
- Osser DN, Roudsari MJ, Manschreck T (). „The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia”. Harvard Review of Psychiatry. 21 (1): 18–40. doi:10.1097/HRP.0b013e31827fd915. PMID 23656760.
- Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S (Aprilie 2005). „Olanzapine for schizophrenia”. The Cochrane Database of Systematic Reviews (2): CD001359. doi:10.1002/14651858.CD001359.pub2. PMID 15846619. Verificați datele pentru:
|date=(ajutor) - Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S (Martie 2010). „Olanzapine versus other atypical antipsychotics for schizophrenia”. The Cochrane Database of Systematic Reviews (3): CD006654. doi:10.1002/14651858.CD006654.pub2. PMC 4169107 . PMID 20238348. Verificați datele pentru:
|date=(ajutor) - Barnes TR (). „Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology” (PDF). J. Psychopharmacol. (Oxford). 25 (5): 567–620. doi:10.1177/0269881110391123. PMID 21292923.[nefuncțională]
- Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Möller HJ (). „World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects”. World J. Biol. Psychiatry. 14 (1): 2–44. doi:10.3109/15622975.2012.739708. PMID 23216388.
- Abou-Setta AM, Mousavi SS, Spooner C, Schouten JR, Pasichnyk D, Armijo-Olivo S, et al. (august 2012). „First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness [Internet]”. PMID 23035275.
- Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU (iulie 2013). „Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis”. Int. J. Neuropsychopharmacol. 16 (6): 1205–18. doi:10.1017/S1461145712001277. PMC 3594563 . PMID 23199972.
- Citrome L (august 2012). „A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia”. Expert Opin Pharmacother. 13 (11): 1545–73. doi:10.1517/14656566.2011.626769. PMID 21999805.
- Lepping P, Sambhi RS, Whittington R, Lane S, Poole R (mai 2011). „Clinical relevance of findings in trials of antipsychotics: systematic review”. Br J Psychiatry. 198 (5): 341–5. doi:10.1192/bjp.bp.109.075366. PMID 21525517.
- Désaméricq G, Schurhoff F, Meary A, Szöke A, Macquin-Mavier I, Bachoud-Lévi AC, Maison P (Februarie 2014). „Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis”. European Journal of Clinical Pharmacology. 70 (2): 127–34. doi:10.1007/s00228-013-1600-y. PMID 24145817. Verificați datele pentru:
|date=(ajutor) - Yatham LN, Kennedy SH, O'Donovan C, et al. (Decembrie 2006). „Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007”. Bipolar Disord. 8 (6): 721–39. doi:10.1111/j.1399-5618.2006.00432.x. PMID 17156158. Verificați datele pentru:
|date=(ajutor) - Selle V, Schalkwijk S, Vázquez GH, Baldessarini RJ (Martie 2014). „Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics”. Pharmacopsychiatry. 47 (2): 43–52. doi:10.1055/s-0033-1363258. PMID 24549862. Verificați datele pentru:
|date=(ajutor) - Maglione M, Maher AR, Hu J, et al. (). „Off-Label Use of Atypical Antipsychotics: An Update”. AHRQ Comparative Effectiveness Reviews. Agency for Healthcare Research and Quality (US). PMID 22132426.
- Narasimhan M, Bruce TO, Masand P (octombrie 2007). „Review of olanzapine in the management of bipolar disorders”. Neuropsychiatr Dis Treat. 3 (5): 579–587. PMC 2656294 . PMID 19300587.
- Rasmussen SA, Chu SY, Kim SY, Schmid CH, Lau J (Iunie 2008). „Maternal obesity and risk of neural tube defects: a metaanalysis”. American Journal of Obstetrics & Gynecology. 198 (6): 611–619. doi:10.1016/j.ajog.2008.04.021. PMID 18538144. Verificați datele pentru:
|date=(ajutor) - McMahon DM, Liu J, Zhang H, Torres ME, Best RG (Februarie 2013). „Maternal obesity, folate intake, and neural tube defects in offspring”. Birth Defects Research Part A: Clinical and Molecular Teratology. 97 (2): 115–122. doi:10.1002/bdra.23113. PMID 23404872. Verificați datele pentru:
|date=(ajutor) - Yeung EY, Chun S, Douglass A, Lau TE (08-05-2017). „Effect of atypical antipsychotics on body weight in geriatric psychiatric inpatients”. SAGE Open Medicine. 5: 2050312117708711. doi:10.1177/2050312117708711. PMC 5431608 . PMID 28540050. Verificați datele pentru:
|date=(ajutor) - Stöllberger C, Lutz W, Finsterer J (Iulie 2009). „Heat-related side-effects of neurological and non-neurological medication may increase heatwave fatalities”. European Journal of Neurology. 16 (7): 879–82. doi:10.1111/j.1468-1331.2009.02581.x. PMID 19453697. Verificați datele pentru:
|date=(ajutor) - Ramankutty G (). „Olanzapine-induced destabilization of diabetes in the absence of weight gain”. Acta Psychiatrica Scandinavica. 105 (3): 235–6; discussion 236–7. doi:10.1034/j.1600-0447.2002.2c257a.x. PMID 11939979.
- Lambert MT, Copeland LA, Sampson N, Duffy SA (). „New-onset type-2 diabetes associated with atypical antipsychotic medications”. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 30 (5): 919–23. doi:10.1016/j.pnpbp.2006.02.007. PMID 16581171.
- Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, Mintz J, Marder SR (). „Novel Antipsychotics”. The Journal of Clinical Psychiatry. 60 (6): 358–63. doi:10.4088/JCP.v60n0602. PMID 10401912.
- McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowski SD (Iulie 2007). „Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison”. The American Journal of Psychiatry. 164 (7): 1050–60. doi:10.1176/ajp.2007.164.7.1050. PMID 17606657. Verificați datele pentru:
|date=(ajutor) - Chiu CC, Chen CH, Chen BY, Yu SH, Lu ML (august 2010). „The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine”. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 34 (6): 866–70. doi:10.1016/j.pnpbp.2010.04.003. PMID 20394794.
- Sacher J, Mossaheb N, Spindelegger C, Klein N, Geiss-Granadia T, Sauermann R, Lackner E, Joukhadar C, Müller M, Kasper S (iunie 2008). „Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers”. Neuropsychopharmacology. 33 (7): 1633–41. doi:10.1038/sj.npp.1301541. PMID 17712347.
- Sowell M, Mukhopadhyay N, Cavazzoni P, Carlson C, Mudaliar S, Chinnapongse S, Ray A, Davis T, Breier A, Henry RR, Dananberg J (Decembrie 2003). „Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp”. The Journal of Clinical Endocrinology and Metabolism. 88 (12): 5875–80. doi:10.1210/jc.2002-021884. PMID 14671184. Verificați datele pentru:
|date=(ajutor) - de Haan L, van Amelsvoort T, Rosien K, Linszen D (). „Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets”. Psychopharmacology. 175 (3): 389–90. doi:10.1007/s00213-004-1951-2. PMID 15322727.
- Luedecke, D; Schöttle, D; Karow, A; Lambert, M; Naber, D (ianuarie 2015). „Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management”. CNS Drugs. 29 (1): 41–6. doi:10.1007/s40263-014-0216-9. PMID 25424243.
- Brambilla G, Mattioli F, Martelli A (). „Genotoxic and carcinogenic effects of antipsychotics and antidepressants”. Toxicology. 261 (3): 77–88. doi:10.1016/j.tox.2009.04.056. PMID 19410629.
- Moncrieff J (Iulie 2006). „Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse”. Acta Psychiatrica Scandinavica. 114 (1): 3–13. doi:10.1111/j.1600-0447.2006.00787.x. PMID 16774655. Verificați datele pentru:
|date=(ajutor)
dailymed.nlm.nih.gov
- „OLANZAPINE (olanzapine) tablet OLANZAPINE (olanzapine) tablet, orally disintegrating [Prasco Laboratories]”. DailyMed. Prasco Laboratories. septembrie 2013. Arhivat din original la . Accesat în .
nytimes.com
- Carey, Benedict (20 septembrie 2005). „Little Difference Found in Schizophrenia Drugs”. The New York Times. Accesat în 3 decembrie 2007. Verificați datele pentru:
|access-date=(ajutor)
researchautism.net
- „Olanzapine and Autism”. Research Autism. 19-12-2017. Accesat în 9 august 2018. Verificați datele pentru:
|access-date=, |date=(ajutor)
rxlist.com
- „Symbyax (Olanzapine and fluoxetine) drug overdose and contraindication information”. RxList: The Internet Drug Index. WebMD. . Arhivat din original la . Accesat în .
- „Symbyax (Olanzapine and fluoxetine) drug overdose and contraindication information”. RxList: The Internet Drug Index. WebMD. . Arhivat din original la . Accesat în .
stutteringhelp.org
- Scott L (Iarna 2006). „Genetic and Neurological Factors in Stuttering”. Stuttering Foundation of America. Verificați datele pentru:
|date=(ajutor)
tga.gov.au
ebs.tga.gov.au
- „PRODUCT INFORMATION OLANZAPINE SANDOZ® 2.5mg/5mg/7.5mg/10mg/15mg/20mg FILM-COATED TABLETS” (PDF). TGA eBusiness Services. Sandoz Pty Ltd. . Accesat în .
tum.de
mediatum.ub.tum.de
- Barnes TR (). „Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology” (PDF). J. Psychopharmacol. (Oxford). 25 (5): 567–620. doi:10.1177/0269881110391123. PMID 21292923.[nefuncțională]
web.archive.org
- „NADAC as of 2018-12-19”. Centers for Medicare and Medicaid Services (în engleză). Arhivat din original la . Accesat în .
- „Important Safety Information for Olanzapine”. Zyprexa package insert. Eli Lilly & Company. . Arhivat din original la . Accesat în .
Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. [...] ZYPREXA (olanzapine) is not approved for the treatment of elderly patients with dementia-related psychosis.
- „OLANZAPINE (olanzapine) tablet OLANZAPINE (olanzapine) tablet, orally disintegrating [Prasco Laboratories]”. DailyMed. Prasco Laboratories. septembrie 2013. Arhivat din original la . Accesat în .
- AstraZeneca Pharmaceuticals (4 aprilie 2006). „Efficacy and Tolerability of Olanzapine, Quetiapine and Risperidone in the Treatment of First Episode Psychosis: A Randomised Double Blind 52 Week Comparison”. AstraZeneca Clinical Trials. AstraZeneca PLC. Arhivat din original la 13-11-2007. Accesat în 3 decembrie 2007.
At week 12, the olanzapine-treated group had more weight gain, a higher increase in [ body mass index ], and a higher proportion of patients with a BMI increase of at least 1 unit compared with the quetiapine and risperidone groups (p<=0.01).
Verificați datele pentru:|archive-date=(ajutor) - „Symbyax (Olanzapine and fluoxetine) drug overdose and contraindication information”. RxList: The Internet Drug Index. WebMD. . Arhivat din original la . Accesat în .
- „Symbyax (Olanzapine and fluoxetine) drug overdose and contraindication information”. RxList: The Internet Drug Index. WebMD. . Arhivat din original la . Accesat în .
zyprexa.com
- „Important Safety Information for Olanzapine”. Zyprexa package insert. Eli Lilly & Company. . Arhivat din original la . Accesat în .
Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. [...] ZYPREXA (olanzapine) is not approved for the treatment of elderly patients with dementia-related psychosis.